Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
CORE Biomedicine secures $21 million Series A financing co-led by UTokyo Innovation Platform and Elikon Venture to advance novel cancer therapies.
PRIVATEJul 28, 2026•1 day ago
Amount Raised
$21 Million
Round Type
Series A
BiotechnologyHealth CareTherapeutics
Investors
Root Venture PartnersVision Incubate Co., Ltd.Yuan Bio Venture CapitalCd CapitalSuzhou Capital Group Co., Ltd.Mitsubishi Ufj Capital Co., Ltd.Inno Pinnacle FundElikon VentureU Tokyo Innovation Platform Co., Ltd.
Description
CORE Biomedicine has completed a $21 million Series A financing aimed at accelerating the development of lineage-based oncology therapies. This financing round was co-led by UTokyo Innovation Platform Co., Ltd. and Elikon Venture, with participation from several other investors. The funding will enable CORE to enhance its research and early clinical development efforts
Company Information
Company
CORE Biomedicine
About
CORE Biomedicine is a biotechnology company pioneering lineage-based precision oncology therapeutics. Founded by former leaders of H3 Biomedicine, the company develops next-generation precision medicines that target core biological pathways defining cancer cell identity. This approach enables the discovery of first- and best-in-class therapies to benefit broader patient populations. CORE is focused on accelerating the development of novel oncology therapies for patients worldwide.
